1. Rootman J, Stewart B, Goldberg RA. Orbital surgery. A conceptual approach. 1

(1)

BIBLIOGRAFIA

1. Rootman J, Stewart B, Goldberg RA. Orbital surgery. A conceptual approach. 1

^st

ed. Philadelphia: Lippincott-Raven Publisher, 1995. p. 353-384.

2. Elgood C. Medicine in Persia. New york: AMS press, 1935.

p. 54-55

3. Forrester JV, Sutherland GR, McDougall IR. Dysthyroid ophthalmopathy: orbital evaluation with B-scan ultrasonography. J Clin Endocrinol Metab 1977; 45:221-24.

4. Enzmann D, Marshall WH Jr, Rosenthal AR, Kriss JP.

Computed tomography in Graves’ ophthalmopathy.

Radiology 1976; 118:615-20.

5. Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbital involvement in Graves’

disease. N Engl J Med 1974; 2901:447-50.

6. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurence of ophthalmopathy in Graves’

disease. Acta Endocrinologica 1989; 120:473-78.

7. Bartalena L, Marcocci C, Pinchera A. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21:168-99.

I

(2)

8. Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14(6):747-93.

9. Bartalena L, Marcocci C, Pinchera A. Graves’

ophthalmopathy: a preventable disease? Eur J Endocrinol 2002; 146:457-61.

10. Tomer Y, Davies TF. The genetic susceptibility to Graves’

disease. Balliere’s Clinical Endocrinology and Metabolism 1997; 11:431-50.

11. Bartley GB. The epidemiologic characteristic and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Transaction of the American ophthalmology society 1994; 92:477-588.

12. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A. More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest 1989;

12:733-37.

13. Prummel MF, Wiersinga WM. Smoking and risk of Graves’

disease. JAMA 1993; 269:479-82.

14. Pfeilshifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol 1996;

45:477-81.

II

(3)

15. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcomes in Graves’ ophthalmo- pathy. Ann Intern Med 1998; 129:632-35.

16. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol 1989; 121:185-89.

17. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 1990; 150:1098-1101.

18. Karlsson AF, Westermark K, Dahlberg PA, Jansson R, Enoksson P. Ophthalmopathy and thyroid stimulation. Lancet 1989; 2:691.

19. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’

ophthalmopathy. N Engl J Med 1998; 338:73-78.

20. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy. Clin Endocrinol 1999; 51:503- 08.

III

(4)

21. Wiersinga WM. Preventing Graves’ ophthalmopathy. N Engl J Med 1998; 338:121-22.

22. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321:1349-52.

23. Bartalena L, Wiersinga WM, Pinchera A. Graves’

ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004; 27:295-301.

24. Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004; 27:216-20.

25. Davies TF. The thyrotropin receptors spread themselves around. J Clin Endocrinol Metab 1994; 79:1232-33.

26. Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A. Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypotesis of Kriss revisited. J Endocrinol Invest 2004; 27:230-36.

27. Lisi S, Marinò M, Pinchera A, et al. Thyroglobulin in orbital tissues from patients with thyroid associated ophthalmopathy:

predominant localization in fibroadipose tissue. Thyroid 2002; 12:351-60.

IV

(5)

28. Mikozami T, Salvi M, Wall JR. Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 2004; 27:221-29.

29. Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall JR. Role of eye muscle antibody measurement in diagnosis of thyroid associated ophthalmopathy: a laboratory update. Endocr Prac 1998; 4:127-31.

30. Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004; 27:237-45.

31. Heufelder AE, Bahn R. Dectection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves’ ophthalmopathy. Eur J Clin Invest 1993; 23:10-17.

32. McLachlan SM, Prummel MF, Rapoport B. Cell mediated or humoral immunity in Graves’ ophthalmopathy? Profiles of T- cell cytokine amplifies by polymerase chain reaction from orbital tissue. J Clin Endocrinol Metab 1994; 78:1070-74.

33. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab 2000; 85:776-80.

34. Hiromatsu Y, Yang D, Bednarczuk T, Mayake I, No K, Inoue Y. Cytokine profile in eye muscle tissue and orbital fat tissue

V

(6)

from patients with thyroid associated ophthalmopathy. J Clin Endocrinol Metab 2000; 85:1194-99.

35. Heufelder AE, Smith J, Gorman CA, Bahn RS. Increased induction of HLA-DR by interferon-γ in cultured retroocular fibroblasts from patients with Graves’ ophthalmopathy and pretibial myxedema. J Clin Endocrinol Metab 1991; 73:307- 13.

36. Heufelder AE. Pathogenesis of Graves’ ophthalmopathy:

recent controversies and progress. Eur J Endocrinol 1995;

132:532-41.

37. Heufelder AE, Bahn RS. Modulation of intercellular adhesion molecule-1 (ICAM-1) by cytokines and Graves’ Igs in cultured Graves’ retroocular fibroblasts. Eur J Clin Invest 1992; 23:10-17.

38. Heufelder AE, Bahn RS. Modulation of Graves’ orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Ophthalmol Vis Sci 1994; 35:120-27.

39. Ajjan RA, Weetman AP. Cytokines in Graves’ disease. In:

Rapoport B, McLachlan S eds. Graves’ disease: pathogenesis and treatment. Norwell: Kluiwer Academic Publ 2000; p. 79- 93.

40. Cao HJ, Smith TJ. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol 1999; 277:1075-85.

VI

(7)

41. Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996; 81:3428-31.

42. Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 2004; 27:246-53.

43. Ludgate M, Baker G. Inducing Graves’ ophthalmopathy. J Endocrinol Invest 2004; 27:211-15.

44. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS.

Stimulation of adipogenesis, peroxisome proliferation activator receptor-γ (PPAR-γ), and thyrotropin receptor by PPAR-γ agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 2002; 87:2352-58.

45. Starkey K, Heufelder AE, Baker G, et al. PPARγ in thyroid eye disease: contraindication to thiazolidenedione use? J Clin Endocrinol Metab 2003; 88:55-59.

46. Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003; 19:155-63.

47. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp Eye Res 1997; 65:311-16.

48. Hiromatsu Y, Yang D, Miyake I, et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts

VII

(8)

from patients with thyroid associated ophthalmopathy. J Clin Endocrinol Metab 1998; 83:121-24.

49. Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1β-induced glycosaminoglycan production by retroocular fibroblasts from normal subjects and Graves’

ophthalmopathy patients. Thyroid 1999; 9:297-303.

50. Heufelder AE, Wenzel BE, Bahn RS. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’

retroocular fibroblasts. J Clin Endocrinol Metab 1992;

73:307-13.

51. Hiromatsu Y, Sato M, Yamada K, Nonaka K. Nicotinamide and 3-aminobenzamide inhibit recombinant interferon-γ- induced HLA-DR antigen expression, but not HLA-A,B,C antigen expression, on cultured human thyroid cells. Clin Endocrinol (Oxf) 1992; 36:91-95.

52. Hiromatsu Y, Sato M, Tanaka K, Ishisaka N, Kamachi J, Nonaka K. Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology 1993; 80:330-32.

53. Jameson JL, Weetman AP. Disorders of the thyroid. In:

Harrison’s principles of internal medicine 16

^th

ed. McGraw- Hill 2005.

VIII

(9)

54. Fledelius HC, Glydensted C. Ultrasonography and computed tomography in orbital diagnosis. With special reference to dysthyroid ophthalmopathy. Acta Ophthalmol (Copenh) 1978; 56:751-62.

55. De Santo LW. The total rehabilitation in Graves’

ophthalmopathy. Laryngoscope 1980; 90:1652-78.

56. Wiersinga WM, Smith T, van der Gaag R, Mouritus M, Koornef L. Clinical presentation of Graves’ ophthalmopathy.

Ophthalmic Res 1989; 21:73-82.

57. Weetman AP. Update: thyroid associated ophthalmopathy.

Autoimmunity 1992; 12:215-22.

58. Hudson HL, Levin L, Feldon SE. Graves’ exophthalmus unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction.

Ophthalmology 1991; 98:1495-99.

59. Trobe JD. Optic nerve involvement in dysthyroidism.

Ophthalmology 1981; 88:488-92.

60. Bartley GB, Gorman CA. Diagnostic criteria for Graves’

ophthalmopathy. Am J Ophthalmol 1995; 119: 792-95.

61. Mourits MP. Graves’ orbitopathy: epidemiology, pathogenesis, clinical features and treatment. 2

^nd

EUGOGO Teaching Course on Graves’ Orbitopathy: Abstract book. Pisa (Italy) June 6-8, 2006.

IX

(10)

62. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73(8):639-44.

63. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12:855-60.

64. El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 2004; 34:482-91.

65. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001; 55:283-303.

66. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42:45-50.

67. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103:958-62.

68. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA et al. The treatment of Graves’

ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:200-06.

X

(11)

69. Asman P. Ophthalmological evaluation in thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2003; 81:437-48.

70. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marinò M, Pinchera A. An update on medical management of Graves’ ophthalmopathy. J Endocrinol Invest 2005; 28:469- 78.

71. Dallow RL, Netland PA. Management of thyroid ophthalmopathy (Graves’ disease). In: Albert DM, Jakobiec FA editors. Principles and Practice of Ophthalmology.

Philadelphia: Saunders; 1994. p. 1905-22.

72. Boulos PR, Hardy I. Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 2004; 15:389-400.

73. Kendall-Taylor P. The management of Graves’

ophthalmopathy. Clin Endocrinol (Oxf) 1989; 31:747-56.

74. Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G et al. Orbital radiotherapy for Graves’

ophthalmopathy. Thyroid 2002; 12:245-50.

75. Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol 2004;

15:479-82.

76. Bartalena L, Marcocci C, Manetti L, Tanda ML, Dell’Unto E, Rocchi R et al. Orbital radiotherapy for Graves’

ophthalmopathy. Thyroid 1998; 8:439-41.

XI

(12)

77. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy:

comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56:1139-44.

78. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. J Endocrinol Invest 1991; 14:853-60.

79. Moore RF. Exophthalmos and limitation of the eye movements of Graves’ disease. Lancet 1920; 2:701.

80. Krönlein RU. Zur Pathologie und operativen Behandlung der Dermoidzysten des Orbita. Beitr Klin Chir 1889; 4:149.

81. Döllinger J. Die Druckentlastung der Augenhohle durch Entfernung der ausseren Orbitalwand bei hochgradigen Exophtalmus (Morbus Basedowii) und Konsekutiver Hornhauterkrankung. Deutsch Med Wochenschr 1911;

37:1898.

82. Lexer E. Die gesamte Wiederherstellungschirurgie. JA Barth, Leipzig, 1931.

83. Anderson E. Ein Fall von schwerem Exophtalmus auf Grund von Morbus Basedowii dei einem 69 Jahrigen Manne operiert nach Döllinger. Acta Opht 1932; 10:396.

XII

(13)

84. Swift GW. Malignant exophthalmos and operative approach.

West J Surg 1935; 43:119.

85. Moran RE. Surgical correction for enophthalmos and exophthalmos. Sect Ophthalm AMA 1937; 109:1622.

86. Tessier P. Expansion chirurgicale de l’orbite. Ann Chir Plast 1969; 14:207.

87. Naffziger HC. Progressive exophthalmos following thyroidectomy: its pathology and treatment. Ann Surg 1931;

94:582.

88. Poppen JL. Exophthalmos: diagnosis and surgical treatment of intractable cases. Am J Surg 1944; 64:64.

89. Welti H, Offret G. Trepanation decompressive de l’orbite pour exophthalmie maligne basedowienne. Med Acad Chir 1942; 68:379.

90. Hamby WB. Orbital decompression for exophthalmos. In:

Clinical Neurosurgery. William & Wilkins, Baltimore, 1970.

91. Backlund EO. Pterimal approach for orbital decompression.

Acta Opht 1968; 46:535.

92. Naffziger HC, Jones OW. The surgical treatment of progressive exophthalmos following thyroidectomy. JAMA 1932; 99:638.

93. Kistner F. Decompression for exophthalmos. JAMA 1939;

112:37.

XIII

(14)

94. Hirsch O, Urbanek J. Behandlung eines exzessiven Exophtalmus (Basedow) durch Entfernung von Orbitalfett von der Kieferhohle aus. Monatsschr. Ohrenheilk 1930;

64:212.

95. Meesman A. Operation Behadlung des Malignes Exophtalmus. Zentralbl.fd Ges. Ophthalmol 1940; 45:161.

96. Sewall EC. Operative control of progressive exophthalmos.

Arch Otolaryng 1936; 24:621.

97. Walsh TE, Ogura JH. Transantral orbital decompression for malignant exophthalmos. Laryngoscope 1957; 67:544.

98. Stell PM. Transantral orbital decompression in malignant exophthalmos. J Laryng Otol 1968; 82:613.

99. Maroon JC, Kennerdel JS. Radical orbital decompression for severe dysthyroid exophthalmos. J Neurosurg 1982; 56:260- 66.

100. Sellari-Franceschini S, Berrettini S, Santoro A, Nardi M, Mazzeo S, Bartalena L, Mazzi B, Tanda ML, Marcocci C, Pinchera A. Orbital decompression in Graves’

ophthalmopathy by medial and lateral wall removal.

Otolaryngology-Head and Neck Surgery 2005; 133:185-89.

101. Wolfe SA. A rationale for the surgical treatment of exophthalmos and exorbitism. J Max Fac Surg 1977; 5:249.

102. Moran RE. The correction of exophthalmos and levator spasm. Plast Reconstruc Surg 1956; 18:411.

XIV

(15)

103. Henderson JW. Relief of eyelid retraction (a surgical approach). Arch Ophthalmol 1965; 74:205.

104. Putterman AM, Urist MJ. Müller muscle-conjuntival resection. Technique for treatment of blepharoptosis. Arch Ophthal 1975; 93:619.

XV